KENILWORTH (NJ) (dpa-AFX) - Moderna, Inc., (MRNA) said it has regained all rights to the respiratory syncytial virus vaccine (mRNA-1172) from Merck, including rights to develop RSV vaccines for adult populations. Merck will complete the phase 1 study and transition the program to Moderna.
Moderna also announced the initiation of dosing in the phase 1 study of its solely owned RSV vaccine candidate (mRNA-1345). This phase 1 study includes initial dosing in adults, followed by age de-escalation into children.
Moderna and Merck will continue their ongoing collaboration in cancer vaccines.
Copyright RTT News/dpa-AFX
© 2020 AFX News
